Novo bestræber sig på at forkorte “time-to-market” for nye lægemidler med op til to tredjedele ved hjælp af AI.
Kunstig intelligens anvendes blandt andet til analyse af forskningsdata og udarbejdelse af dokumenter. En central rolle i denne udvikling spilles af virksomhedens afdeling i Indien, hvor der nu lægges vægt på AI-ekspertise og effektivisering af arbejdet frem for masserekruttering.
Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming obesity drugs market.
“Historically, from ‘last patient, last visit’ to first filing might have been a year and a half. What we’re able to do now by implementing AI is bring that time down by months,” John Dawber, managing director for global business services, told a Reuters summit on Friday.